People: Progenics Pharmaceuticals Inc (PGNX.O)

Summary

Name	Age	Since	Current Position
Peter Crowley	55	2010	Independent Chairman of the Board
Mark Baker	57	2011	Chief Executive Officer, Director
Paul Maddon	52	2012	Vice Chairman of the Board
Angelo Lovallo		2012	Principal Financial Officer, Principal Accounting Officer
Robert Israel	55	2011	Senior Vice President - Medical Affairs & Clinical Research
William Olson	49	2001	Senior Vice President - Research & Development
Nitya Ray	59	2004	Senior Vice President - Manufacturing
Stephen Goff	60	1993	Independent Director
David Scheinberg	56	1996	Independent Director
Nicole Williams	68	2007	Independent Director
Amy Martini			IR Contact

» Insider Trading

Biographies

Name	Description
Peter Crowley	Mr. Peter J. Crowley is Independent Chairman of the Board of Progenics Pharmaceuticals Inc. Mr. Crowley is Operating Partner of MTS Health Partners, L.P., a New York based healthcare merchant bank, and an Operating Partner at JH Partners, a private equity firm where he has been active since 2008. Mr. Crowley retired in 2008 as Managing Director of the Healthcare Investment Banking group at Oppenheimer & Company (formerly CIBC World Markets), which he headed since 1995, with responsibility for public and private financing and advisory services for biotechnology, pharmaceutical, medical device and healthcare services companies. Mr. Crowley serves on the board of directors of the New York Eye and Ear Infirmary, Continuum Hospitals, the Foundation Fighting Blindness and Rye Country Day School. He is also a board member at La Perla, an Italian lingerie company, Ovidad, a hair styling company, and Napastyle, a specialty food and furnishings company. Mr. Crowley holds an M.B.A. in finance from Columbia University Graduate School of Business and a B.A. in economics from Harvard University.
Mark Baker	Mr. Mark R. Baker, J.D., is Chief Executive Officer, Director of Progenics Pharmaceuticals Inc. Mr. Baker joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President – Corporate, in 2009 became President, and has been CEO since March 2011. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm, Dewey Ballantine. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.
Paul Maddon	Dr. Paul J. Maddon, M.D., Ph.D., is Vice Chairman of the Board of Progenics Pharmaceuticals Inc. He served as Chief Science Officer of the Company, effective March 14, 2012. Prior to founding Progenics, from 1981 to 1988 Dr. Maddon performed research at the Howard Hughes Medical Institute at Columbia University in the laboratory of Dr. Richard Axel. Dr. Maddon serves as a trustee of Columbia and as a member of the Board of Visitors of its Medical Center. He also serves on a variety of scientific advisory boards of the National Institutes of Health, the Rockefeller University and Columbia. He received a B.A. in biochemistry and mathematics, an M.D., and a Ph.D. in biochemistry and molecular biophysics, all from Columbia.
Angelo Lovallo
Robert Israel	Dr. Robert J. Israel, M.D. is Senior Vice President - Medical Affairs & Clinical Research of Progenics Pharmaceuticals Inc. Dr. Israel has been with Progenics since 1994. He previously held oncology positions at Sandoz Pharmaceuticals Corporation and Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania, and completed an oncology fellowship at the Memorial Sloan-Kettering Institute for Cancer Research. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.
William Olson	Dr. William C. Olson, Ph.D., is Senior Vice President - Research & Development of Progenics Pharmaceuticals Inc. He also has been with the Company since 1994, and was a scientist at Johnson & Johnson and MicroGeneSys, Inc., a biotechnology company, for five years before joining Progenics. Dr. Olson has served on scientific review committees of the National Institutes of Health and has co-authored more than 40 articles for peer-reviewed scientific journals. He received a Ph.D. from the Massachusetts Institute of Technology and a B.S. from the University of North Dakota, both in chemical engineering.
Nitya Ray	Dr. Nitya G. Ray, Ph.D., is Senior Vice President - Manufacturing of Progenics Pharmaceuticals Inc. He joined the Company in 2001. Prior to joining Progenics, Dr. Ray served as Director of Bioprocess Development at Ortec International, and before that held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP Manufacturing and Process Development, ultimately as Research Leader, Biopharmaceuticals. Early in his career he developed process technology for biopharmaceutical manufacturing at Verax Corporation. Dr. Ray received an M.S. and Ph.D. in chemical and biochemical engineering from Rutgers University and a B.S. in chemical engineering from Jadavpur University, India.
Stephen Goff	Dr. Stephen P. Goff, Ph.D. is Independent Director of Progenics Pharmaceuticals Inc. Dr. Goff is the Higgins Professor in the Departments of Biochemistry and Molecular Biophysics, and Microbiology and Imunology at Columbia University, has been a scientific advisor to us since 1988. He received an A.B. in biophysics from Amherst College and a Ph.D. in biochemistry from Stanford University. Dr. Goff performed post-doctoral research at the Massachusetts Institute of Technology in the laboratory of Dr. David Baltimore.
David Scheinberg	Dr. David A. Scheinberg, M.D., Ph.D. is Independent Director of Progenics Pharmaceuticals Inc. Dr. Scheinberg has been a scientific advisor to the company since 1994. Dr. Scheinberg has been associated with the Sloan-Kettering Institute for Cancer Research since 1986, where he is the Vincent Astor Chair and Member, Leukemia Service; Chairman, Molecular Pharmacology and Chemistry Program; Chairman, Experimental Therapeutics Center; and Head, Laboratory of Hematopoietic Cancer Immunochemistry. He also holds the positions of Professor of Medicine and of Pharmacology, Weill-Cornell Medical College. He received a B.A. from Cornell University and an M.D. and a Ph.D. in pharmacology and experimental therapeutics from The Johns Hopkins University School of Medicine.
Nicole Williams	Ms. Nicole S. Williams, M.B.A. is Independent Director of Progenics Pharmaceuticals Inc. She was elected to the Board in 2007 after retiring in 2006 as Chief Financial Officer of Abraxis Bioscience Inc., a biopharmaceutical company, and President of its Abraxis Pharmaceutical Products division, positions she assumed upon the 2006 merger of American Pharmaceutical Partners, Inc. and American Bioscience Inc. From 2002 to 2006, Ms. Williams was the Executive Vice President and Chief Financial Officer of American Pharmaceutical Partners, as well as President from 2005. Previously, she was Executive Vice President and Chief Financial Officer of R.P. Scherer, Inc., a global drug delivery company. Ms. Williams is President of the Nicklin Capital Group, Inc., a firm she founded in 1999 to invest in and provide consulting to early-stage technology companies in the Midwest. She is a director and Audit Committee chair at Intercept Pharmaceuticals, Inc., a privately-held biotechnology company, and previously held the same positions at Orchid Cellmark, Inc., a DNA identity testing service company, until its purchase last year by LabCorp. Ms. Williams received her Demi-License en Science Politique from the University of Geneva, Switzerland, her License en Science Politique from the Graduate Institute of International Affairs, University of Geneva, Switzerland and her M.B.A. from the Graduate School of Business, University of Chicago. In 2007, she earned a Certificate of Director Education from the National Association of Corporate Directors.
Amy Martini

Basic Compensation

Name	Fiscal Year Total
Peter Crowley	--
Mark Baker	2,523,060
Paul Maddon	1,057,250
Angelo Lovallo	--
Robert Israel	904,109
William Olson	--
Nitya Ray	--
Stephen Goff	--
David Scheinberg	--
Nicole Williams	--
Amy Martini	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Peter Crowley	0	0
Mark Baker	50,000	249,500
Paul Maddon	1,688,775	24,746,750
Angelo Lovallo	0	0
Robert Israel	248,000	3,189,113
William Olson	0	0
Nitya Ray	0	0
Stephen Goff	0	0
David Scheinberg	0	0
Nicole Williams	0	0
Amy Martini	0	0

Insider Trading

Name	Shares Traded	Price
BAKER MARK ROBERT	50	$5.34
BAKER MARK ROBERT	500	$5.31
BAKER MARK ROBERT	100	$5.36
SCHEINBERG DAVID A	1,250	$4.81
SCHEINBERG DAVID A	1,250	$2.47
BAKER MARK ROBERT	535	$2.72
BAKER MARK ROBERT	227	$2.75
BAKER MARK ROBERT	500	$2.71
BAKER MARK ROBERT	315	$2.83
BAKER MARK ROBERT	900	$2.82
BAKER MARK ROBERT	1,142	$3.01
BAKER MARK ROBERT	1,000	$2.13
BAKER MARK ROBERT	100	$2.12
BAKER MARK ROBERT	100	$2.13
BAKER MARK ROBERT	300	$2.12
BAKER MARK ROBERT	7	$2.14
BAKER MARK ROBERT	100	$2.13
BAKER MARK ROBERT	11,800	$1.96
BAKER MARK ROBERT	49,793	$1.82
BAKER MARK ROBERT	48,833	$1.69
BAKER MARK ROBERT	1,162	$2.96
BAKER MARK ROBERT	1,036	$3.32
BAKER MARK ROBERT	815	$4.23
BAKER MARK ROBERT	346	$10.04
ISRAEL ROBERT J	1,000	$5.33

» Full list on Insider Trading

People: Progenics Pharmaceuticals Inc (PGNX.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: